Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. Five ...

Abstracts and additional details can be found at the SIRS 2025 website.

Explore Reviva Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RVPH. Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports.

Reviva Pharmaceuticals Holdings, Inc.’s (NASDAQ:RVPH) CEO Laxminarayan Bhat participated in a video series which covered several topics germane to the company. This included reviewing the most ...

On November 14 th, 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported third quarter 2024 financial and operational results and filed its Form 10-Q with the SEC. Reviva provided ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Short interest in Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) decreased during the last reporting period, falling from 3.79M to 2.85M. This put 6.84% of the company's publicly available ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Quince Therapeutics (QNCX – Research Report), ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...